有投资者向康希诺提问, 尊敬的康希诺:贵公司的通用肺炎疫苗BPBV还在处于上市的早期阶段,除过贵公司即将上市的13价肺炎疫苗外,是否今年有计划申报多价肺炎(比如24价)疫苗,谢谢!公司回答表示,尊敬的投资人您好,结合肺炎疫苗市场情况,公司已布局更高价的肺炎结合疫苗,以增强肺炎产品组合的竞争力,尚处于临床前的开发阶段,未来如有阶段性进展,将及时分享。谢谢!
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.